Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral Corp., revealed a new website highlighting its explorations into the multi-billion-dollar drug delivery and genome-mapping market. The new website replaces the prior version and can be found at www.rainbowbiosciences.com.
The revamped site details the company’s new partnership with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.
RBCC also told investors that it is close to partnering with a cutting-edge genome-mapping facility in Houston capable of helping doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans. The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017.
“The partnerships that we’re targeting could help usher in a new era of healthcare: personalized medicine,” said RBCC CEO Patrick Brown. “We see big growth in store for this sector, and Rainbow BioSciences’ improved website will help us keep shareholders, potential investors and other interested parties up to date on our latest activities to bring these revolutionary technologies to a pharmacy or clinic near you.”
Let us hear your thoughts: Rainbow Coral Corp. Message Board